1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Joincare Pharmaceutical Group Industry Co.,Ltd.

Joincare Pharmaceutical Group Industry Co.,Ltd.

600380.SS
Joincare Pharmaceutical Group Industry Co.,Ltd.CN flagShanghai Stock Exchange
9.93
CNY
-0.32
- -
18.17BMarket Cap
Joincare Pharmaceutical Group Industry Co.,Ltd.
600380.SS
(Shanghai Stock Exchange)

Recent

price

9.93

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.56
2.78
3.43
3.64
4.34
5.01
5.63
6.89
6.87
6.18
6.94
8.22
9.05
8.77
8.34
8.32
8.07
Revenue per Share
0.42
0.15
0.1
0.16
0.21
0.24
0.26
1.36
0.43
0.46
0.58
0.69
0.79
0.76
0.74
0.73
0.74
Basic EPS, GAAP
0.3
0.12
-0.08
-0.2
0.1
0.39
0.66
0.89
0.72
0.83
1.13
0.54
1.49
1.47
1.42
1.71
-0.49
Free Cash Flow per Basic Share
0.01
0.01
0.08
0.1
0.12
0.19
0.18
0.24
0.27
0.19
0.19
0.2
0.21
0.25
0.25
0.24
0.24
Dividend per Share
1.46
1.61
1.87
1.99
2.15
2.29
2.45
3.88
4.17
3.81
4.2
4.72
5.48
5.96
6.6
7.23
6.72
Book Value per Share
2.55
2.64
2.71
2.94
3.19
3.61
4.76
7.97
9.25
8.3
9.12
9.47
10.65
10.98
11.59
12.29
11.46
Tangible Book Value per Share
1,747
1,724
1,708
1,708
1,708
1,724
1,726
1,563
1,632
1,938
1,948
1,935
1,894
1,898
1,874
1,830
1,895
Basic Weighted Avg Shares
4,473
4,792
5,850
6,220
7,418
8,642
9,722
10,779
11,204
11,980
13,522
15,904
17,143
16,646
15,619
15,216
15,283
Sales/Revenue/Turnover
24.67
13.27
10.47
12.52
11.78
12.3
11.86
14.48
13.75
16.9
20.49
18.16
19.22
20.29
22.55
20.94
22.5
Operating Margin (%)
230
279
353
336
420
490
540
522
515
523
547
620
838
1,054
813
818
- -
Depreciation Expense
740
262
170
274
354
412
451
2,133
699
894
1,120
1,328
1,503
1,443
1,387
1,336
1,395
Net Income, GAAP
10.13
17.31
19.07
19.27
14.58
16.26
17.47
21.34
15.78
15.06
12.6
11.5
16.26
17.73
16.56
14.89
16.79
Effective Tax Rate (%)
16.55
5.47
2.9
4.4
4.78
4.77
4.64
19.79
6.24
7.47
8.29
8.35
8.77
8.67
8.88
8.78
9.13
Profit Margin (%)
1,653
2,638
1,592
1,562
1,473
1,212
3,412
7,400
8,939
9,212
10,602
10,013
13,423
14,014
13,735
14,304
14,293
Working Capital
115
1,248
1,241
1,584
1,673
1,185
1,694
1,196
499
- -
370
852
3,254
3,138
2,445
1,594
2,307
LT Debt
5,317
5,460
5,591
6,024
6,542
7,307
9,335
13,618
16,297
17,384
19,237
20,180
22,020
22,640
23,400
24,368
23,537
Total Equity
17.49
8.01
6.81
7.97
8.87
10.05
9.26
8.57
6.93
8.5
11.48
11.17
10.7
9.81
10.17
9.41
10.04
Return on Invested Capital (%)
11.7
1.4
-0.19
0.66
1.68
1.46
0.62
-2.36
0.39
-0.05
-1.71
0.62
1
0.61
-0.41
-0.45
-0.69
Return on Capital (%)
35.25
9.82
5.68
8.31
10.01
10.82
11.06
41.48
10.87
12.61
14.4
15.34
15.4
13.3
11.71
10.43
11.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,851
2,760
2,669
LT Borrowings
2,425
2,538
2,286
LT Finance Leases
20
24
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,874
1,829
1,829
Market Capitalization
20,652
21,941
20,899

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
23,006
23,038
23,391
Cash, Cash Equivalents & STI
14,941
14,936
14,977
Accounts Receivable, Net
2,430
2,590
2,886
Inventories
2,621
2,485
2,321
Total Current Liabilities
9,271
8,770
9,098
Payables & Accruals
- -
- -
- -
ST Debt
2,851
2,760
2,669
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.5%
4.87%
4.14%
Free Cash Flow
28.08%
26.11%
17.59%
Net Income, GAAP
38.8%
4.02%
-3.68%
Sales/Revenue/Turnover
6.09%
2.75%
-2.58%
Total Cash Common Dividend
3.94%
4.83%
-4.5%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,340
3,895
3,664
3,721
15,619
2025
4,089
3,809
3,738
- -
15,216
2026
3,721
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
- -
- -
- -
0.74
2025
0.23
- -
- -
- -
0.73
2026
0.23
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.25
2025
0.01
- -
- -
- -
0.24
2026
0.01
- -
- -
- -
- -
Similar Companies
Kissei Pharmaceutical Co., Ltd. (4547.T)
Medcolcanna Organics Inc. (MCCNF)
Glenmark Life Sciences Limited (GLS.BO)
Boiron S.A. (BOIRF)
LFTD Partners Inc. (LIFD)
Digicann Ventures Inc. (AGFAF)
Business
Joincare Pharmaceutical Group Industry Co., Ltd. operates as an integrated pharmaceutical enterprise, primarily centered on the research, development, manufacturing, and distribution of diverse healthcare solutions, largely within China. Established in 1992 and based in Shenzhen, the company has grown to encompass a broad portfolio. Its operations span the creation of chemical drug preparations, addressing therapeutic areas such as respiratory, gastrointestinal, anti-infective, reproductive, and neuropsychiatric conditions. Furthermore, the company develops traditional Chinese medicine formulations, including those targeting anti-tumor applications and common ailments. Beyond finished pharmaceuticals, Joincare is a key provider of chemical active pharmaceutical ingredients (APIs) and intermediates, notably within the cephalosporin, statin, and carbapenem families. The firm also contributes to medical diagnostics with a range of reagents and equipment, including advanced in-vitro diagnostics (IVD) devices and platforms for autoimmune detection. Completing its comprehensive offering are various health and wellness products. The company maintains a strong commitment to innovation, driven by substantial investments in research and development and a strategic focus on novel drugs and sophisticated high-barrier complex formulations, leveraging platforms for monoclonal antibodies and inhaled preparations. Recent initiatives include advancing new anti-tumor drugs through clinical trials and developing influenza treatments, alongside expanding its global market presence for its diverse product lines.